Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients' Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).
Fiche publication
Date publication
juillet 2023
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François, Dr NARDIN Charlée
Tous les auteurs :
Nardin C, Hennemann A, Diallo K, Funck-Brentano E, Puzenat E, Heidelberger V, Jeudy G, Samimi M, Lesage C, Boussemart L, Peuvrel L, Rouanet J, Brunet-Possenti F, Gerard E, Seris A, Jouary T, Saint-Jean M, Puyraveau M, Saiag P, Aubin F
Lien Pubmed
Résumé
The long-term effectiveness of immune checkpoint inhibitor (ICI) rechallenge for progressive or recurrent advanced melanoma following previous disease control induced by ICI has not been thoroughly described in the literature.
Mots clés
anti-CTLA-4, anti-PD1, disease control, immune checkpoint inhibitor, immunotherapy, melanoma, re-induction, rechallenge, response, retreatment, safety
Référence
Cancers (Basel). 2023 07 10;15(14):